AR087700A1 - Inhibidores de aldh-2 en el tratamiento de adicciones - Google Patents
Inhibidores de aldh-2 en el tratamiento de adiccionesInfo
- Publication number
- AR087700A1 AR087700A1 ARP120103172A ARP120103172A AR087700A1 AR 087700 A1 AR087700 A1 AR 087700A1 AR P120103172 A ARP120103172 A AR P120103172A AR P120103172 A ARP120103172 A AR P120103172A AR 087700 A1 AR087700 A1 AR 087700A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- aldh
- inhibitors
- Prior art date
Links
- 206010012335 Dependence Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) donde: R¹ es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o fenilo opcionalmente sustituido; R² es hidrógeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido o fenilo opcionalmente sustituido; R³ es hidrógeno, ciano, amino opcionalmente sustituido, alquilo, alcoxi o halo; y X, Y y Z se seleccionan de -CR⁴- y -N-, en el cual R⁴ es hidrógeno, alquilo, alcoxi inferior o halo; o una de sus sales farmacéuticamente aceptables. Reivindicación 10: Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz del compuesto de la reivindicación 1 y uno o más vehículos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529164P | 2011-08-30 | 2011-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087700A1 true AR087700A1 (es) | 2014-04-09 |
Family
ID=46982916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103172A AR087700A1 (es) | 2011-08-30 | 2012-08-28 | Inhibidores de aldh-2 en el tratamiento de adicciones |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8673966B2 (es) |
| EP (1) | EP2751090A1 (es) |
| JP (1) | JP2014525457A (es) |
| KR (1) | KR20140057634A (es) |
| CN (1) | CN103764640A (es) |
| AR (1) | AR087700A1 (es) |
| AU (1) | AU2012300209B2 (es) |
| BR (1) | BR112014004943A2 (es) |
| CA (1) | CA2845796A1 (es) |
| EA (1) | EA201490270A1 (es) |
| HK (1) | HK1199729A1 (es) |
| IL (1) | IL230746A0 (es) |
| MX (1) | MX2014002270A (es) |
| TW (1) | TWI468403B (es) |
| WO (1) | WO2013033377A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3341355T3 (pl) * | 2015-10-09 | 2021-03-08 | Northwestern University | Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego |
| WO2023244574A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2023244563A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| WO1999058124A1 (en) * | 1998-05-12 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| EP1645272A3 (en) * | 1998-05-12 | 2008-11-05 | The Endowment For Research In Human Biology, Inc. | Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse |
| CN1671373A (zh) * | 2002-06-27 | 2005-09-21 | 人类生物研究基金公司 | 用于抑制aldh的化合物 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| JP2011510072A (ja) * | 2008-01-24 | 2011-03-31 | ギリアード・パロ・アルト・インコーポレイテッド | 嗜癖の処置におけるａｌｄｈ−２インヒビター |
-
2012
- 2012-08-28 AR ARP120103172A patent/AR087700A1/es unknown
- 2012-08-28 TW TW101131184A patent/TWI468403B/zh not_active IP Right Cessation
- 2012-08-30 JP JP2014528596A patent/JP2014525457A/ja active Pending
- 2012-08-30 WO PCT/US2012/053110 patent/WO2013033377A1/en not_active Ceased
- 2012-08-30 EP EP12769522.9A patent/EP2751090A1/en not_active Withdrawn
- 2012-08-30 EA EA201490270A patent/EA201490270A1/ru unknown
- 2012-08-30 CN CN201280041692.3A patent/CN103764640A/zh active Pending
- 2012-08-30 HK HK15100156.3A patent/HK1199729A1/xx unknown
- 2012-08-30 BR BR112014004943A patent/BR112014004943A2/pt not_active Application Discontinuation
- 2012-08-30 MX MX2014002270A patent/MX2014002270A/es not_active Application Discontinuation
- 2012-08-30 US US13/599,368 patent/US8673966B2/en active Active
- 2012-08-30 AU AU2012300209A patent/AU2012300209B2/en not_active Ceased
- 2012-08-30 CA CA2845796A patent/CA2845796A1/en not_active Abandoned
- 2012-08-30 KR KR1020147008253A patent/KR20140057634A/ko not_active Withdrawn
-
2014
- 2014-01-30 IL IL230746A patent/IL230746A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012300209B2 (en) | 2015-01-22 |
| US8673966B2 (en) | 2014-03-18 |
| CN103764640A (zh) | 2014-04-30 |
| US20130231325A1 (en) | 2013-09-05 |
| TWI468403B (zh) | 2015-01-11 |
| JP2014525457A (ja) | 2014-09-29 |
| BR112014004943A2 (pt) | 2017-03-21 |
| WO2013033377A1 (en) | 2013-03-07 |
| HK1199729A1 (en) | 2015-07-17 |
| AU2012300209A1 (en) | 2013-04-04 |
| EP2751090A1 (en) | 2014-07-09 |
| CA2845796A1 (en) | 2013-03-07 |
| IL230746A0 (en) | 2014-03-31 |
| MX2014002270A (es) | 2015-01-16 |
| TW201331197A (zh) | 2013-08-01 |
| KR20140057634A (ko) | 2014-05-13 |
| EA201490270A1 (ru) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| EA201300200A1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
| BR112014010407A2 (pt) | compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel | |
| MX385616B (es) | Inhibidores de cdk | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| EA201790661A3 (ru) | Ингибиторы вируса гепатита c | |
| PE20160200A1 (es) | Inhibidores de bromodominios | |
| PE20161073A1 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| ES2531056T3 (es) | Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1 | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| ES2662444T3 (es) | Derivado de piridina | |
| CR20110343A (es) | Inhibidores de proteína cinasa | |
| EA201490724A1 (ru) | Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| CR11483A (es) | Inhibidores de peptido desformilasa | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |